{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T12:22:10Z","timestamp":1794226930076,"version":"4.9.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Recurrence remains a major cause of mortality in early breast cancer (EBC), and conventional follow-up often identifies relapse only after clinically detectable disease has emerged. Circulating tumor DNA\u2013based minimal residual disease (ctDNA-MRD) testing offers the possibility of detecting molecular relapse earlier and refining recurrence-risk assessment during follow-up. This narrative review examines the evolving role of ctDNA-MRD in EBC, focusing on assay interpretation, longitudinal surveillance, MRD-guided trial design, and clinical implementation. Prospective studies consistently show that postoperative or surveillance ctDNA positivity is associated with an increased risk of recurrence. However, test performance and interpretation vary with assay characteristics and sampling strategies, and whether treatment initiated solely on the basis of MRD positivity can improve patient outcomes remains unresolved. The central challenge is no longer simply to detect residual disease earlier, but to determine when and how that information should influence care. Further prospective validation, assay standardization, clear pathways for uncertain findings, and patient-centered implementation will be needed before ctDNA-MRD can be integrated into routine management of EBC.<\/jats:p>","DOI":"10.3389\/fonc.2026.1850732","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:21:25Z","timestamp":1787566885000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["From detection to action: ctDNA-MRD surveillance and translational strategies in early breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Jing","family":"Feng","sequence":"first","affiliation":[{"name":"Department of Breast Center, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujun","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Breast Center, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast Center, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China","place":["Mianyang, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01816","article-title":"De-escalated neoadjuvant trastuzumab-emtansine with or without endocrine therapy versus trastuzumab with endocrine therapy in HR+\/HER2+ early breast cancer: 5-year survival in the WSG-ADAPT-TP trial","volume":"41","author":"Harbeck","year":"2023","journal-title":"J Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01745-8","article-title":"Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155\u2008746 women in 151 trials","volume":"404","year":"2024","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.102390","article-title":"Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis","volume":"9","author":"Nader-Marta","year":"2024","journal-title":"ESMO Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00908","article-title":"Circulating tumor DNA and late recurrence in high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer","volume":"40","author":"Lipsyc-Sharf","year":"2022","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00456","article-title":"Serial postoperative circulating tumor DNA assessment has strong prognostic value during long-term follow-up in patients with breast cancer","volume":"8","author":"Shaw","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1038\/ncomms9839","article-title":"Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma","volume":"6","author":"De Mattos-Arruda","year":"2015","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13058-025-02016-7","article-title":"Identification of minimal residual disease using the clonesight test for ultrasensitive ctDNA detection to anticipate late relapse in early breast cancer","volume":"27","author":"Comino-M\u00e9ndez","year":"2025","journal-title":"Breast Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105286","article-title":"Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer","volume":"10","author":"Elliott","year":"2025","journal-title":"ESMO Open"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.01.021","article-title":"Whole genome sequencing-powered ctDNA sequencing for breast cancer detection","volume":"36","author":"Garcia-Murillas","year":"2025","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.SABCS24-GS3-01","article-title":"Abstract GS3-01: Circulating tumor DNA surveillance in ZEST, a randomized, phase 3, double-blind study of niraparib or placebo in patients w\/ triple-negative breast cancer or HER2+ BRCA-mutated breast cancer with molecular residual disease after definitive therapy","volume":"31","author":"Turner","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B11","unstructured":"ZEST Trial Offers Insights for Using Ctdna to Predict Breast Cancer Recurrence\n          \n          2024"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer","volume":"34","author":"Turner","year":"2023","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy552","article-title":"Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses","volume":"30","author":"Abbosh","year":"2019","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41523-024-00653-3","article-title":"Use of ctDNA in early breast cancer: analytical validity and clinical potential","volume":"10","author":"Panet","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0703-0","article-title":"Sensitive tumour detection and classification using plasma cell-free DNA methylomes","volume":"563","author":"Shen","year":"2018","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat4921","article-title":"Enhanced detection of circulating tumor DNA by fragment size analysis","volume":"10","author":"Mouliere","year":"2018","journal-title":"Sci Transl Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","article-title":"Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin","volume":"164","author":"Snyder","year":"2016","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1804134115","article-title":"Size-tagged preferred ends in maternal plasma DNA shed light on the production mechanism and show utility in noninvasive prenatal testing","volume":"115","author":"Sun","year":"2018","journal-title":"Proc Natl Acad Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.104296","article-title":"Detection of minimal residual disease and prediction of recurrence in breast cancer using a plasma-only circulating tumor DNA assay","volume":"10","author":"Janni","year":"2025","journal-title":"ESMO Open"},{"key":"B22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41698-025-00876-y","article-title":"Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology","volume":"9","author":"Bartolomucci","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105636","article-title":"Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop","volume":"114","author":"De Jager","year":"2025","journal-title":"eBioMedicine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1208715109","article-title":"Detection of ultra-rare mutations by next-generation sequencing","volume":"109","author":"Schmitt","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1593","article-title":"Low-pass whole-genome sequencing of circulating cell-free DNA demonstrates dynamic changes in genomic copy number in a squamous lung cancer clinical cohort","volume":"25","author":"Chen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvae014","article-title":"External quality assessment on molecular tumor profiling with circulating tumor DNA-based methodologies routinely used in clinical pathology within the COIN Consortium","volume":"70","author":"Van Der Leest","year":"2024","journal-title":"Clin Chem"},{"key":"B28","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s10549-024-07508-2","article-title":"Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer","volume":"209","author":"Garcia-Murillas","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00607-1","article-title":"Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment","volume":"10","author":"Zaikova","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114159","article-title":"A review of trials investigating ctDNA-guided adjuvant treatment of solid tumors: the importance of trial design","volume":"207","author":"Verschoor","year":"2024","journal-title":"Eur J Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41523-024-00642-6","article-title":"Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients","volume":"10","author":"Alba-Bernal","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2025.100286","article-title":"Cancer in a drop: liquid biopsy highlights from San Antonio Breast Cancer Symposium (SABCS) 2024","volume":"7","author":"Pontolillo","year":"2025","journal-title":"J Liq Biopsy"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-055821","article-title":"Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1","volume":"12","author":"Berger","year":"2022","journal-title":"BMJ Open"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00555-1","article-title":"Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial","volume":"23","author":"Bidard","year":"2022","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.annonc.2023.08.004","article-title":"Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030","volume":"34","author":"Parsons","year":"2023","journal-title":"Ann Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03725-4","article-title":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","volume":"31","author":"Mittendorf","year":"2025","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S542704","article-title":"Clinical management of circulating tumor DNA in breast cancer: detection, prediction, and monitoring","volume":"17","author":"Lu","year":"2025","journal-title":"Breast Cancer: Targets Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/1078-0432.CCR-23-2326","article-title":"Comparison of circulating tumor DNA assays for molecular residual disease detection in early-stage triple-negative breast cancer","volume":"30","author":"Coakley","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103687","article-title":"Association of post-operative ctDNA detection with outcomes of patients with early breast cancers","volume":"9","author":"Cutts","year":"2024","journal-title":"ESMO Open"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03579-w","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial","volume":"31","author":"Tie","year":"2025","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"B42","unstructured":"Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development: Guidance for Industry\n          \n          2024"},{"key":"B43","unstructured":"Ctdna-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive\/HER2-Negative Breast Cancer. Clinical Trial Registration NCT06970912"},{"key":"B44","unstructured":"A Single Arm Phase II Trial of Circulating Tumor DNA-Guided Adjuvant Therapy With Elacestrant in Adults With Hormone Receptor-Positive, HER2-Negative Breast Cancers at Risk for Late Recurrence (CATE). Clinical Trial Registration NCT06923527"},{"key":"B45","unstructured":"Framework for Integrating Change in Ctdna Levels in Advanced Cancer Clinical Trials to Support Meta-Analyses for Intermediate Endpoint Validation\n          \n          2024"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01766-x","article-title":"Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma","volume":"126","author":"Woof","year":"2022","journal-title":"Br J Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-023-01473-y","article-title":"I just wanted more\u201d: hereditary cancer syndromes patients\u2019 perspectives on the utility of circulating tumour DNA testing for cancer screening","volume":"32","author":"Adi-Wauran","year":"2024","journal-title":"Eur J Hum Genet"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2024.1270","article-title":"Budget impact analysis of circulating tumor DNA testing for colon cancer in commercial health and Medicare Advantage plans","volume":"5","author":"Li","year":"2024","journal-title":"JAMA Health Forum"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70641","article-title":"Health economic evaluations of circulating tumor DNA testing for cancer screening: systematic review","volume":"14","author":"Rui","year":"2025","journal-title":"Cancer Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13046-025-03322-w","article-title":"A scoping review of factors influencing the implementation of liquid biopsy for cancer care","volume":"44","author":"Sheriff","year":"2025","journal-title":"J Exp Clin Canc Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-1073","article-title":"Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: Subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4\/6 inhibitor and in clinical subgroups","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103701","article-title":"Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: Should health authorities consider post hoc data to inform priority access","volume":"9","author":"Valenza","year":"2024","journal-title":"ESMO Open"},{"key":"B54","unstructured":"Interim Esr1 Genomic Sample Routing Pathway\n          \n          2025"},{"key":"B55","unstructured":"ESR1 Ctdna Testing for Breast Cancer\n          \n          2025"},{"key":"B56","unstructured":"Implementation of Genomic Testing for ESR1 Variants: Interim ESR1 Genomic Sample Routing Pathway, 20 January 2025\u201331 March 2025\n          \n          2025"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.02.009","article-title":"ESMO Precision Oncology Working Group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice","volume":"36","author":"Westphalen","year":"2025","journal-title":"Ann Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2024.2413289","article-title":"Detection of genomic alterations in liquid biopsies from patients with non-small cell lung cancer using FoundationOne Liquid CDx: A cost-effectiveness analysis","volume":"27","author":"Isla","year":"2024","journal-title":"J Med Econ"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107794","article-title":"The cost-effectiveness of including liquid biopsy into molecular profiling strategies for newly diagnosed advanced non-squamous non-small cell lung cancer in an Asian population","volume":"191","author":"Liu","year":"2024","journal-title":"Lung Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2025-012454","article-title":"Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and\/or chemotherapy","volume":"13","author":"Andrews","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-3612","article-title":"ctDNA clearance as an early indicator of improved clinical outcomes in advanced NSCLC treated with TKI: Findings from an aggregate analysis of eight clinical trials","volume":"31","author":"Andrews","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12885-025-13526-0","article-title":"Multiple time points for detecting circulating tumor DNA to monitor the response to neoadjuvant therapy in breast cancer: A meta-analysis","volume":"25","author":"Niu","year":"2025","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1850732\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:21:28Z","timestamp":1787566888000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1850732\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":62,"alternative-id":["10.3389\/fonc.2026.1850732"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1850732","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fonc.2026.1850732.s001","asserted-by":"subject"}]},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"article-number":"1850732"}}